Table. Clinical Performance of Transvaginal Ultrasonography and an Experimental Assay for Endometrial Cancer Detection Across Risk Estimates in a Hypothetical Population of 10 000 Women With PMBa.
| Endometrial Cancer Risk in PMB, % | Test Sensitivity, % | Test Specificity, % | PPV, % | cNPV, % | No. of Patients With Biopsy | No. of Biopsies per case of Cancer |
|---|---|---|---|---|---|---|
| 5 | ||||||
| Transvaginal ultrasonography | 98.0 | 35.0 | 7.4 | 0.3 | 6665 | 13.6 |
| Methylation assay | 90.0 | 50.0 | 8.7 | 1.0 | 5200 | 11.6 |
| 10 | ||||||
| Transvaginal ultrasonography | 98.0 | 35.0 | 14.3 | 0.3 | 6830 | 7.0 |
| Methylation assay | 90.0 | 50.0 | 16.7 | 2.2 | 5400 | 6.0 |
| 15 | ||||||
| Transvaginal ultrasonography | 98.0 | 35.0 | 21.0 | 1.0 | 6995 | 4.8 |
| Methylation assay | 90.0 | 50.0 | 24.1 | 3.4 | 5600 | 4.1 |
Abbreviations: cNPV, complement of the negative predictive value; PMB, postmenopausal bleeding; PPV, positive predictive value.
a
Assumes 10 000 women with PMB; sensitivity and specificity estimates for transvaginal ultrasonography and methylation were obtained from the literature.